Last reviewed · How we verify
glecaprevir/pibrentasvir tablets
Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.
Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication. Used for Chronic hepatitis C virus infection (all genotypes 1-6), treatment-naïve and treatment-experienced patients, Hepatitis C virus infection in patients with compensated cirrhosis.
At a glance
| Generic name | glecaprevir/pibrentasvir tablets |
|---|---|
| Also known as | Mavyret |
| Sponsor | Raymond T. Chung, MD |
| Drug class | Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor) |
| Target | HCV NS3/4A protease and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Glecaprevir is a pangenotypic NS3/4A protease inhibitor that prevents HCV polyprotein processing. Pibrentasvir is a pangenotypic NS5A inhibitor that disrupts viral RNA replication and virion assembly. Together, they provide potent inhibition across all HCV genotypes with a high barrier to resistance.
Approved indications
- Chronic hepatitis C virus infection (all genotypes 1-6), treatment-naïve and treatment-experienced patients
- Hepatitis C virus infection in patients with compensated cirrhosis
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
- Asthenia
Key clinical trials
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (PHASE1, PHASE2)
- Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder (PHASE2, PHASE3)
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) (PHASE3)
- Glecaprevir/Pibrentasvir for the Treatment of PTSD (PHASE2, PHASE3)
- Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PHASE2)
- A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation (EARLY_PHASE1)
- Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (NA)
- Utilization of Hepatitis C Positive Kidneys in Negative Recipients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glecaprevir/pibrentasvir tablets CI brief — competitive landscape report
- glecaprevir/pibrentasvir tablets updates RSS · CI watch RSS
- Raymond T. Chung, MD portfolio CI